The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients
Diana Hedevang Christensen,1,2 Erzsébet Horváth-Puhó,1 Morten Schmidt,1 Christian Fynbo Christiansen,1 Lars Pedersen,1 Bente Lomholt Langdahl,2 Reimar Wernich Thomsen1 1Department of Clinical Epidemiology, 2Department of Endocrinology and Internal Medicine, Aarhus Un...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-08-01
|
| Series: | Clinical Epidemiology |
| Online Access: | http://www.dovepress.com/the-impact-of-preadmission-oral-bisphosphonate-use-on-30-day-mortality-peer-reviewed-article-CLEP |
| _version_ | 1818000226374385664 |
|---|---|
| author | Christensen DH Horváth-Puhó E Schmidt M Christiansen CF Pedersen L Langdahl BL Thomsen RW |
| author_facet | Christensen DH Horváth-Puhó E Schmidt M Christiansen CF Pedersen L Langdahl BL Thomsen RW |
| author_sort | Christensen DH |
| collection | DOAJ |
| description | Diana Hedevang Christensen,1,2 Erzsébet Horváth-Puhó,1 Morten Schmidt,1 Christian Fynbo Christiansen,1 Lars Pedersen,1 Bente Lomholt Langdahl,2 Reimar Wernich Thomsen1 1Department of Clinical Epidemiology, 2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark Purpose: Bisphosphonate use has been associated with increased risk of fatal stroke. We examined the association between preadmission use of oral bisphosphonates and 30-day mortality following hospitalization for stroke. Patients and methods: We conducted a nationwide population-based cohort study using medical databases and identified all patients in Denmark with a first-time hospitalization for stroke between 1 July 2004 and 31 December 2012 (N=100,043). Cox regression was used to compute adjusted hazard ratios as a measure of 30-day mortality rate ratios (MRRs) associated with bisphosphonate current use (prescription filled within 90 days prior to the stroke) or recent use (prescription filled in the 90–180 days prior to the stroke). Current use was further classified as new or long-term use. Results: We found 51,982 patients with acute ischemic stroke (AIS), 11,779 with intracerebral hemorrhage (ICH), 4,528 with subarachnoid hemorrhage (SAH), and 31,754 with unspecified stroke. Absolute 30-day mortality risks were increased among current vs nonusers of bisphosphonates for AIS (11.9% vs 8.5%), ICH (43.2% vs 34.5%), SAH (40.3% vs 23.2%), and unspecified strokes (18.8% vs 14.0%). However, in adjusted analyses, current bisphosphonate use did not increase 30-day mortality from AIS (MRR, 0.87; 95% confidence interval [CI]: 0.75, 1.01); ICH (MRR, 1.05; 95% CI: 0.90, 1.23); SAH (MRR, 1.15; 95% CI: 0.83, 1.61); or unspecified stroke (MRR, 0.94; 95% CI: 0.81, 1.09). Likewise, no association with mortality was found for recent use. Adjusted analyses by type of bisphosphonate showed increased mortality following stroke among new users of etidronate (MRR, 1.40; 95% CI: 1.01, 1.93) and reduced mortality after AIS among current users of alendronate (MRR, 0.87; 95% CI: 0.74, 1.02). Conclusion: We found no overall evidence that preadmission bisphosphonate use increases 30-day mortality following stroke. Keywords: prognosis, oral bisphosphonates, stroke, mortality, cardiovascular disease, osteoporosis treatment |
| first_indexed | 2024-04-14T03:19:14Z |
| format | Article |
| id | doaj.art-afbbe58fe2ad4965adf2642f122cf094 |
| institution | Directory Open Access Journal |
| issn | 1179-1349 |
| language | English |
| last_indexed | 2024-04-14T03:19:14Z |
| publishDate | 2015-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Epidemiology |
| spelling | doaj.art-afbbe58fe2ad4965adf2642f122cf0942022-12-22T02:15:22ZengDove Medical PressClinical Epidemiology1179-13492015-08-012015default38138923296The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patientsChristensen DHHorváth-Puhó ESchmidt MChristiansen CFPedersen LLangdahl BLThomsen RWDiana Hedevang Christensen,1,2 Erzsébet Horváth-Puhó,1 Morten Schmidt,1 Christian Fynbo Christiansen,1 Lars Pedersen,1 Bente Lomholt Langdahl,2 Reimar Wernich Thomsen1 1Department of Clinical Epidemiology, 2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark Purpose: Bisphosphonate use has been associated with increased risk of fatal stroke. We examined the association between preadmission use of oral bisphosphonates and 30-day mortality following hospitalization for stroke. Patients and methods: We conducted a nationwide population-based cohort study using medical databases and identified all patients in Denmark with a first-time hospitalization for stroke between 1 July 2004 and 31 December 2012 (N=100,043). Cox regression was used to compute adjusted hazard ratios as a measure of 30-day mortality rate ratios (MRRs) associated with bisphosphonate current use (prescription filled within 90 days prior to the stroke) or recent use (prescription filled in the 90–180 days prior to the stroke). Current use was further classified as new or long-term use. Results: We found 51,982 patients with acute ischemic stroke (AIS), 11,779 with intracerebral hemorrhage (ICH), 4,528 with subarachnoid hemorrhage (SAH), and 31,754 with unspecified stroke. Absolute 30-day mortality risks were increased among current vs nonusers of bisphosphonates for AIS (11.9% vs 8.5%), ICH (43.2% vs 34.5%), SAH (40.3% vs 23.2%), and unspecified strokes (18.8% vs 14.0%). However, in adjusted analyses, current bisphosphonate use did not increase 30-day mortality from AIS (MRR, 0.87; 95% confidence interval [CI]: 0.75, 1.01); ICH (MRR, 1.05; 95% CI: 0.90, 1.23); SAH (MRR, 1.15; 95% CI: 0.83, 1.61); or unspecified stroke (MRR, 0.94; 95% CI: 0.81, 1.09). Likewise, no association with mortality was found for recent use. Adjusted analyses by type of bisphosphonate showed increased mortality following stroke among new users of etidronate (MRR, 1.40; 95% CI: 1.01, 1.93) and reduced mortality after AIS among current users of alendronate (MRR, 0.87; 95% CI: 0.74, 1.02). Conclusion: We found no overall evidence that preadmission bisphosphonate use increases 30-day mortality following stroke. Keywords: prognosis, oral bisphosphonates, stroke, mortality, cardiovascular disease, osteoporosis treatmenthttp://www.dovepress.com/the-impact-of-preadmission-oral-bisphosphonate-use-on-30-day-mortality-peer-reviewed-article-CLEP |
| spellingShingle | Christensen DH Horváth-Puhó E Schmidt M Christiansen CF Pedersen L Langdahl BL Thomsen RW The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients Clinical Epidemiology |
| title | The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients |
| title_full | The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients |
| title_fullStr | The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients |
| title_full_unstemmed | The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients |
| title_short | The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients |
| title_sort | impact of preadmission oral bisphosphonate use on 30 day mortality following stroke a population based cohort study of 100 043 patients |
| url | http://www.dovepress.com/the-impact-of-preadmission-oral-bisphosphonate-use-on-30-day-mortality-peer-reviewed-article-CLEP |
| work_keys_str_mv | AT christensendh theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT horvathpuhoe theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT schmidtm theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT christiansencf theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT pedersenl theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT langdahlbl theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT thomsenrw theimpactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT christensendh impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT horvathpuhoe impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT schmidtm impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT christiansencf impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT pedersenl impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT langdahlbl impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients AT thomsenrw impactofpreadmissionoralbisphosphonateuseon30daymortalityfollowingstrokeapopulationbasedcohortstudyof100043patients |